Patents Assigned to Yeshiva University
-
Mercaptosuccinyl glycyl-glycyl-glycine a complex thereof with Tc-99m, and methods of making the same
Patent number: 4883862Abstract: The novel compound mercaptosuccinyl glycyl-glycyl-glycine (MSG.sub.3) and a stable complex thereof with technetium-99m (Tc-99m) having utility as a renal agent. MSG.sub.3 is made by coupling glycyl-glycyl-glycine with S-acetyl-mercapto succinic anhydride.Type: GrantFiled: April 13, 1988Date of Patent: November 28, 1989Assignee: Albert Einstein College of Medicine - of Yeshiva UniversityInventors: Lakshman R. Chervu, Kuldeep K. Bhargava, M. Donald Blaufox -
Patent number: 4883650Abstract: The novel N-hydroxysuccinimide ester of iodohippuric acid (IH-OSU), capable of forming a stable conjugate with a protein. The iodohippuric acid is preferably orthoiodohippuric acid (OIH) and radiolabeled. A protein compound useful as a radiolable comprises a stable conjugate of a protein and the N-hydroxysuccinimide ester of radiolabeled iodohippuric acid.Type: GrantFiled: April 13, 1988Date of Patent: November 28, 1989Assignee: ALbert Einstein College of Medicine - of Yeshiva UniversityInventors: Kuldeep K. Bhargava, Lakshman R. Chervu, M. Donald Blaufox
-
Patent number: 4870026Abstract: A purified form of a DNA virus which has the following characteristics: molecular weight greater than 2.times.10.sup.6 Daltons; substantial immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC HB 8058; substantially no immunoreactivity towards an anti-HBsAg monoclonal antibody obtained from cell line ATCC CRL 8018; concentration dependent immunoreactivity towards polyclonal IgG anti-HBsAg antibodies, which increases with increased concentration of said DNA virus; discrete particulate form when observed by immunoelectron microscopy in the presence of IgM antibodies from cell line ATCC HB 8058; the DNA of said virus showing hybridization with DNA from hepatitis B viral DNA; and said DNA virus showing, in chimpanzees, infectivity having the characteristics of non A, non B hepatitis.Type: GrantFiled: February 8, 1984Date of Patent: September 26, 1989Assignees: The General Hospital Corporation, The Albert Einstein College of Medicine of Yeshiva UniversityInventors: Jack Wands, David Shafritz
-
Patent number: 4861864Abstract: A soluble form of the neutralizing antigen or rotavirus is provided. The antigen is formed by cloning DNA coding for VP7 protein into an expression vector and preparing deletion mutants coding for a soluble cell secreted neutralizing antigen. The preparation of the deletion mutants includes the removal of the DNA sequences coding for those amino acids of the VP7 protein responsible for its normal intracellular location and non-secretion characteristics. The deletion mutant may be used in the formation of stably transformed animal cell lines which contiuously secrete the antigen, or in the production of certain yeast strains which produce the soluble antigen with appropriate glycosylation.Type: GrantFiled: June 13, 1988Date of Patent: August 29, 1989Assignee: Albert Einstein College of Medicine of Yeshiva University (a Div. of Yeshiva University)Inventors: Paul H. Atkinson, A. Richard Bellamy, Gerald W. Both, Marianne S. Poruchynsky, Chiara Tyndall
-
Patent number: 4857454Abstract: A method is described for kinetic measurement of enzyme activity bound to a solid matrix which improves both the sensitivity and speed of one immunoassay method. The immunoassay typically consists of reaction of the analyte with two specific antibodies, one fixed to the surface of a polymeric bead or wall of a test tube, the other added in solution and labeled by covalent coupling to an enzyme. By reaction between analyte and both antibodies, the enzyme-labeled antibody becomes fixed to the surface in a quantity proportional to the quantity of the analyte. After washing sufficiently to remove unreacted enzyme-labeled antibody, fixed enzyme activity is measured by incubation with a substrate and measurement of the rate of the reaction catalyzed. Fixation of the enzyme causes the reaction products to be localized near the surface. To measure the concentration of reactant or product repeatedly during the reaction, the solution must be mixed before each measurement, which can interfere with the measurement.Type: GrantFiled: April 9, 1987Date of Patent: August 15, 1989Assignee: a Division of Yeshiva University Albert Einstein College of Medicine of Yeshiva UniversityInventors: Lawrence F. Freundlich, Vadiraja V. Murthy, Arthur Karmen
-
Patent number: 4822745Abstract: A method for determining the reticulocyte population in a blood sample includes the steps of determining the average cell size of the blood sample, partitioning the sample by centrifugation through a medium of known density so as to provide a fraction enriched with neocytes, determining the average cell size of the fraction, comparing the average cell size of the sample to the average cell size of the fraction and utilizing this comparison to provide a determination of the population of reticulocytes in the sample.Type: GrantFiled: December 5, 1986Date of Patent: April 18, 1989Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Edward R. Burns, Barry Wenz, Shraga N. Goldberg
-
Patent number: 4770636Abstract: The cognometer is a portable electronic device programmed for repeated, rapid, automated assessment and monitoring of memory and concentration. The memory monitor randomly generates data and displays the same in a common format, tests the user's comprehension of such data, tests the immediate recall of such data, and tests the delayed recall of such data. The concentration monitor randomly generates a long multi-digit number and displays the same, tests the user's comprehension of such number, and tests the concentration of the user by requiring the user to enter such number while the number is displayed, but without any position cue.Type: GrantFiled: April 10, 1987Date of Patent: September 13, 1988Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Herman Buschke
-
Patent number: 4714613Abstract: A selective method of suppressing the growth of cells which express a viral antigen on the surface thereof, which comprises administering to the cells a growth suppressing amount of a monoclonal antibody against said viral antigen, especially a method of suppressing the growth of hepatocytes or hepatoma cells persistently infected with HBsAg which comprises administering to the cells a growth suppressing or lethal amount of a complement fixing monoclonal IgM or IgG.sub.2a antibody against HBsAg.Type: GrantFiled: September 30, 1982Date of Patent: December 22, 1987Assignees: The Albert Einstein College of Medicine of Yeshiva University, The General Hospital CorporationInventors: Daniel Shouval, David A. Shafritz, Jack R. Wands
-
Patent number: 4692416Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus.Type: GrantFiled: November 16, 1983Date of Patent: September 8, 1987Assignee: Yeshiva UniversityInventor: Betty A. Diamond
-
Patent number: 4690905Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus, and as therapeutic reagents in methods to remove the anti-native DNA antibodies from the serum of patients with systemic lupus erythematosus.Type: GrantFiled: November 30, 1983Date of Patent: September 1, 1987Assignee: Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventor: Betty A. Diamond
-
Patent number: 4674496Abstract: Double-lumen tube adaptors for use with either single or dual anesthesia or ventillating machines enable the various features thereof to be utilized without airway disconnection or clamping, interruption of ventilation or the use of unreliable mechanical elements. The adaptor having a single machine-side entry port comprises a support frame and a pair of linear axially-extending cylindrical tubes in substantially parallel disposition extending rotatably through the frame, each of the tubes defining externally of the frame at one end a patient-side exit port adapted for communication with a patient via one lumen of a double-lumen tube and at the other end an entry port with a removable cap. Each of the tubes further defines within the frame interior intermediate the entry and exit ports an aperture extending appreciably in a direction transverse to the tube axes.Type: GrantFiled: September 30, 1986Date of Patent: June 23, 1987Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Edward Svadjian, Paul L. Goldiner
-
Patent number: 4645669Abstract: A method and culture solution are disclosed which enable in vivo emplacement of differentiated cells derived from in vitro culturing of differentiated cells, with significant retention of their differentiated character. In an alternative embodiment, in vivo culturing of differentiated cells is contemplated. Through the use of extracellular matrix fibers, specifically derived from connective tissue, as culture substrates, the method also discloses the isolation of the connective tissue fibers and their preparation as a culture substrate. This method provides significantly higher survival and attachment rates, and often significantly improved growth properties for in vivo or in vitro cultures of differentiated cells, especially epithelial, over the current methods for culturing these cells.Type: GrantFiled: October 4, 1982Date of Patent: February 24, 1987Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Lola C. M. Reid
-
Patent number: 4642292Abstract: A method is disclosed for isolation of connective tissue fibers, called biomatrix, containing a significant portion of the extracellular matrix, i.e., basement membrane components and components of the ground substance. The connective tissue fibers isolated by this method provide significantly higher survival and attachment rates, and often significantly improved growth properties, for in vitro cultures of differentiated cells, especially epithelial cells, over current culture substrates which do not contain these fibers.Type: GrantFiled: June 6, 1983Date of Patent: February 10, 1987Assignee: Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventors: Lola C. M. Reid, Marcos Rojkind
-
Patent number: 4600690Abstract: There is disclosed a method for immunoassay and/or competitive binding assay, wherein an excess amount of unlabeled antigen is added after the start of the reaction between the labeled ligand, the unlabeled ligand, and the binding agent or antibody, to saturate or flood the antibody binding sites. This provides increased sensitivity allowing for more reliable and precise measurements of ligands including antigens than heretofore. The present method extends the scope of applicability of competitive binding technique for assay of hormones, drugs and other compounds.Type: GrantFiled: July 19, 1983Date of Patent: July 15, 1986Assignee: Albert Einstein College of Medicine of Yeshiva University, A division of Yeshiva UniversityInventors: Arthur Karmen, Fred D. Lasky
-
Patent number: 4528453Abstract: A dual collimator designed for an Anger camera (gamma camera), to permit measurement of cardiac performance on a beat-to-beat basis. Special all-purpose (SAP) and special high-sensitivity (SHS) collimator sections can be interchanged without movement of the gamma camera or patient. Thus, left-ventricular regions of interest delineated on SAP multigated images can be transferred to SHS high sensitivity images to generate beat-to-beat volume curves. Preliminary balloon studies demonstrated an excellent correlation between ejection fractions calculated with the two collimators: 5>0.99, n=17, p<0.001. Varying the volume of an adjacent "right ventricle" balloon failed to alter significantly the count rate from the "left ventricle" balloon's region of interest. Preliminary results on 12 patients, comparing standard-camera ejection fractions with average beat-to-beat ejection fractions, showed that it is possible to measure cardiac function on a beat-to-beat basis with a single-crystal gamma camera.Type: GrantFiled: July 30, 1982Date of Patent: July 9, 1985Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Sherman L. Heller
-
Patent number: 4501815Abstract: A method, solid-state culture support and culture solution are disclosed which enables successful in vitro culturing of differentiated cells, with significant retention of their differentiated character. Through the use of extracellular matrix fibers, specifically derived from connective tissue, as culture substrates, the method also discloses the isolation of the connective tissue fibers and their preparation as a culture substrate. This method provides significantly higher survival and attachment rates, and often significantly improved growth properties for in vitro cultures of differentiated cells, especially epithelial, over the current methods for culturing these cells.This method also significantly enables certain differentiated cells to retain much of their normal enzymatic activities.Furthermore, this method enables certain differentiated cells to retain to a high degree, their ability to secrete substances, such as hormones.Type: GrantFiled: June 25, 1982Date of Patent: February 26, 1985Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Lola C. M. Reid, Marcos Rojkind
-
Patent number: 4491574Abstract: The present invention is directed to a development for alleviating the adverse side-effects of taking non-steroid analgesics and anti-inflammatory agents such as aspirin, by also ingesting vitamin A (or B-carotene) formulations. It has been found that vitamin A ingestion has a salutary and therapeutic effect, in that the vitamin A decreases toxicity, including ulcerogenesis, due to ingestion of such agents, e.g. aspirin. Aspirin per se is a very effective medication with pronounced analgesic properties, including the temporary relief of minor aches and pains, and is widely used (in small amounts) with no ill effects. However, since aspirin is a mild anti-coagulant, it sometimes causes bleeding of stomach ulcers, or aggravates pre-existing conditions of that nature. Thus the concomitant administration of vitamin A per se to humans taking aspirin is very effective in decreasing toxicity and inhibiting ulcerogenesis and bleeding in the stomach.Type: GrantFiled: March 2, 1983Date of Patent: January 1, 1985Assignee: Albert Einstein College of Medicine of Yeshiva University, a division of Yeshiva UniversityInventors: Eli Seifter, Giuseppe Rettura
-
Patent number: 4463098Abstract: An in vitro method for identifying alcoholism and alcohol abuse in humans is disclosed which comprises the isolation and measurement of a unique and stable form of glycosylated hemoglobin.Type: GrantFiled: October 3, 1983Date of Patent: July 31, 1984Assignee: Albert Einstein College of Medicine of Yeshiva University a Division of Yeshiva UniversityInventor: Henry D. Hoberman
-
Patent number: 4418059Abstract: A composition comprising a nucleosidic anti-tumor agent esterified with a carboxylic acid-containing steroid is described. These steroid ester derivatives of, for example, a deoxyuridine compound provide enhanced anti-tumor effects in chemotherapy as compared to the corresponding nucleosides alone.Type: GrantFiled: July 20, 1981Date of Patent: November 29, 1983Assignees: Montefiore Medical Center, The Albert Einstein College of Medicine at Yeshiva UniversityInventor: Iraj Lalezari
-
Patent number: 4352887Abstract: A method, solid-state culture support and culture solution are disclosed which enables successful in vitro culturing of differentiated cells, with significant retention of their differentiated character. Through the use of extra-cellular matrix fibers, specifically derived from connective tissue, as culture substrates, the method also discloses the isolation of the connective tissue fibers and their preparation as a culture substrate. This method provides significantly higher survival and attachment rates, and often significantly improved growth properties for in vitro cultures of differentiated cells, especially epithelial, over the current methods for culturing these cells.This method also significantly enables certain differentiated cells to retain much of their normal enzymatic activities.Furthermore, this method enables certain differentiated cells to retain to a high degree, their ability to secrete substances, such as hormones.Type: GrantFiled: October 29, 1979Date of Patent: October 5, 1982Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Lola C. M. Reid, Marcos Rojkind